{"id":14226,"date":"2011-10-27T08:30:00","date_gmt":"2011-10-27T06:30:00","guid":{"rendered":"http:\/\/www.fedaiisf.it\/farmindustria-troppo-tempo-per-approvare-i-farmaci\/"},"modified":"2011-10-27T08:30:00","modified_gmt":"2011-10-27T06:30:00","slug":"farmindustria-troppo-tempo-per-approvare-i-farmaci","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/farmindustria-troppo-tempo-per-approvare-i-farmaci\/","title":{"rendered":"Farmindustria: too much time to approve drugs"},"content":{"rendered":"<p style=\"margin: 0cm 0cm 10pt\" class=\"MsoNormal\"><font size=\"3\"><font face=\"Calibri\">On average, in Italy the time to have access to medicines, even innovative ones, &quot;are considerably longer, because in addition to national approval we have the approval of regional formularies which undoubtedly extend the times compared to other countries&quot;. This was stated by the president of Farmindustria, Massimo Scaccabarozzi, on the sidelines of a conference on the new frontiers of market access. \u00abFrom a survey recently carried out\u00bb adds Scaccabarozzi \u00abit emerged, in fact, that to be included in all Regions, the times, albeit with regional differences, are on average 200-230 days from publication in the Official Gazette by the Italian Medicines Agency\u00bb. And he adds: \u00abIt is true that the Ministry of Health has recently ordered that products for which innovativeness is recognized at a central level must be immediately made available at a regional level but we have not yet seen the implementation of this bill. When it is fully applied, we will probably have reached an important milestone for Italian patients who will no longer have discrimination&quot;. As for the role of market access, Sacccabarozzi added, &quot;the problem does not only concern innovative products but all products, even those already on the market, because it is not said that they have access to the market for the entire life of the product&quot;. According to the president of Farmindustria, in fact, &quot;situations can arise such that in the life cycle of the product some products, due to decisions taken at a regional level, can have different accesses in one region rather than another&quot;. Therefore, he concludes, &quot;it is very important that there are specialized figures who are able to fully understand how to work to ensure that Italian patients are granted access to therapies, not just innovative ones&quot;.<\/p>\n<p><\/font><\/font><\/p>\n<p style=\"margin: 0cm 0cm 10pt\" class=\"MsoNormal\"><em style=\"mso-bidi-font-style: normal\"><span style=\"line-height: 115%; font-size: 10pt\"><font face=\"Calibri\">Pharmacist33 \u2013 27 October 2011<\/p>\n<p><\/font><\/span><\/em><\/p>","protected":false},"excerpt":{"rendered":"<p>In media, in Italia il tempo per avere accesso ai farmaci, anche innovativi, &laquo;sono notevolmente pi&ugrave; lunghi, perch&eacute; oltre all&#8217;approvazione nazionale abbiamo l&#8217;approvazione dei prontuari regionali che indubbiamente dilatano i tempi rispetto ad altri Paesi&raquo;. Lo afferma il presidente di Farmindustria, Massimo Scaccabarozzi, a margine di un convegno sulle nuove frontiere del market access. &laquo;Da &hellip;<\/p>","protected":false},"author":1,"featured_media":9846,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[90],"tags":[],"class_list":["post-14226","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-fedaiisf-archivio-storico"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/14226","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=14226"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/14226\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/9846"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=14226"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=14226"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=14226"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}